Skip to main content

Table 1 Comparison of mDSI/mHD index evaluation for initially rejected and finally accepted volumes

From: Quality assurance of radiotherapy in the ongoing EORTC 1420 “Best of” trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure

Index

mDSI (SD)

mHD (SD)

Volumes(n = 67)

First

Final

Difference

First

Final

Difference

Planning organ-at-risk volume of the brainstem (3)

0.74 (0.16)

0.75 (0.14)

0.01 (0.02)

8.94 (4.26)

7.88 (3.38)

− 1.1 (1.1)

Cervical esophagus (4)

0.49 (0.10)

0.33 (0.16)

− 0.16 (0.13)

27.22 (11.98)

18.83 (8.44)

− 8.4 (14.0)

Cricoid pharyngeal inlet (5)

0.36 (0.22)

0.38 (0.09)

0.03 (0.20)

13.42 (6.75)

13.19 (3.87)

− 0.2 (9.6)

Contralateral sub-mandibular gland (1)

0.83 (.)

0.83(.)

0.00(.)

5.37 (.)

5.37 (.)

0.0 (.)

Extended oral cavity—PTV (5)

0.76 (0.02)

0.84 (0.08)

0.08 (0.06)

26.36 (4.22)

15.56 (9.19)

− 10.8 (9.7)

Glottis (3)

0.43 (0.19)

0.56 (0.15)

0.14 (0.34)

13.28 (7.63)

8.58 (4.89)

− 4.7 (12.3)

Mandible (6)

0.88 (0.04)

0.91 (0.02)

0.03 (0.03)

19.84 (8.59)

6.75 (4.98)

− 13.1 (8.8)

Pharyngeal constrictor muscles (8)

0.47 (0.16)

0.59 (0.09)

0.12 (0.12)

30.34 (8.83)

19.70 (3.65)

− 10.6 (8.4)

Prophylactic PTV (19)

0.70 (0.13)

0.78 (0.05)

0.07 (0.13)

26.23 (16.33)

15.64 (4.59)

− 10.6 (17.1)

Therapeutic PTV (8)

0.64 (0.15)

0.70 (0.10)

0.06 (0.11)

11.14 (4.05)

10.17 (2.31)

− 1.0 (3.7)

Planning organ-at-risk volume of the spinal cord (3)

0.78 (0.07)

0.80 (0.09)

0.01 (0.02)

6.61 (2.73)

6.68 (2.80)

0.1 (1.1)

Supraglottic larynx (2)

0.42 (0.31)

0.41 (0.29)

− .01 (0.02)

21.03 (18.35)

23.33 (15.09)

2.3 (3.3)